Intervention effects of rutaecarpine in type 2 diabetic obese rats

Chinese Pharmacological Bulletin

Volumn 26, Issue 7, 2010, Pages 872-876

  Nie, Xu Qiang ^a   Yu, Lin Hua ^a   Chen, Huai Hong ^b   Zhao, Tong Feng ^b   Bian, Ka ^c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

High fat diet; Insulin resistance; Obesitas; Rutaecarpine; SD rats; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KIDNEY ENZYME; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PANCREAS ENZYME; RUTAECARPINE; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77958055386     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (Volume I) [S]. Beijing: China Medical Science and Technology Press, 2010:160.
2. Duan X, Ling F. The pharmacologic action of rutacarpine [J]. Chin Arch Tradit Chin Med, 2007,25(9):1857-9.
3. Min H, Li Y J. The research on pharmacologic action of rutacarpine [J]. Central South Pharmacy, 2008,6(4):451-3.
4. Li D, Luo D, Guo R, et al. Calcitonin generelated peptide mediated depressor effect of rutaecarpine in spontaneously hypertensive rats [J]. Central South Pharm, 2007,5(5):420-3.
5. Iwata H, Tezuka Y, Kadota S, et al. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and Limonin from Evodia fruit extract [J]. Drug Metab Pharmacokinet, 2005,20(1):34-45.
6. Bernardis L L, Patterson B D. Correlation between 'Lee index' and carcass fat content in weanling and adult female rats with hypothalamic lesions [J]. J Endocrinol, 1968,40(4):527-8.
7. Talpur N, Echard B, Ingram C, et al. Effects of a novelformulation of essential oil on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study [J]. Diabetes Obes Metab, 2005,7(2):193-9.
8. Liang H X, Yuan H Y, Li H D, et al. Observation of stability of a simple type 2 diabetic rat model: combination of high-fat diet-fed and low-dose streptozotocin-induced diabetic rat [J]. Chin Phamacol Bull, 2008,24(4):551-5.
9. Kim S J, Lee S J, Lee S, et al. Rutecarpine ameliorates bodyweight gain through the inhibition of orexigenic neuropeptides NPY and AgRP in mice [J]. Biochem Biophys Res Commun, 2009,389(3):437-42.
10. Ding J S, Gao R, Li D, et al. Solid dispersion of rutaecarpine improved its antihypertensive effect in spontaneously hypertensive rats [J]. Biopharm Drug Dispos, 2008,29(9):495-500.
11. Jeon T W, Jin C H , Lee S K, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice [J]. Toxicol Lett, 2006,164(2):155-66.
12. Shin Y W, Bae E A, Cai X F, et al. In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents [J]. Biol Pharm Bull, 2007,30(1):197-9.
13. Ko H C, Wang Y H, Liou K T, et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells [J]. Eur J Pharmacol, 2007,555(2-3):211-7.
14. Woo H G, Lee C H, Noh M S, et al. Rutaecarpine, a quinazolino-carboline alkaloid, inhibits prostaglandin production in RAW264.7 maemphages [J]. Planta Med, 2001,67(6):505-9.